Calling the reports completely misleading, fallacious, and ill-informed the Health Ministry said, "The government of India and the national regulator Central Drugs Standard Control Organisation (CDSCO) have followed a scientific approach and prescribed norms in approving the Covid-19 vaccines for emergency use authorization."
Ella, Chairman, and MD of Bharat Biotech, which produces Covaxin, met state Minister for Large and Medium Industries Dr. Murugesh R. Nirani, in Hyderabad on Friday, stated the official press release from the ministry of large and medium industries.
The study by 'bioRxiv', an open-access preprint repository for the biological sciences, shared on Tuesday that its study shows that administration of Covaxin booster dose will enhance the vaccine effectiveness against the Delta variant infection and give protection against the Omicron variants BA.1.1 and BA.2.
According to the Union Health Ministry, dedicated centres can be established for the same.
The development has come after the World Health Organisation approved Covaxin for emergency use listing last week.
The approval by Australia comes when the Bharat Biotech-manufactured Covid-19 vaccine is seeking an approval from the WHO for Covaxin.
"The Prime Minister expressed satisfaction over G20's decision to come up with the 15 per cent minimum Corporate Tax. It was at the 2014 G20 Summit that the Prime Minister had first proposed this idea of a minimum corporate tax in order to prevent to some extent the evasion of taxes," Foreign secretary Harsh Shringla said.
Miss Banerjee asked if the photo of the Prime Minister can be there on vaccination certificates, "then will the death certificates for persons who died of Covid carry the same?"
An expert panel of DCGI has recommended granting emergency use authorisation (EUA) to Bharat Biotech's Covaxin for children aged 2 to 18 with certain conditions.
The WHO's EUL approval for Covaxin was expected by 5 October as WHO's Strategic Advisory Group of Experts on Immunization (SAGE) was scheduled to meet on this day to make its recommendations on Bharat Biotech's Covaxin for Emergency Use Listing. The process has been delayed as more technical data has been sought from the pharma major.
